默沙东(MRK.US)“first-in-class”疗法获FDA批准

智通财经03-27

智通财经APP获悉，3月27日，FDA官方网站显示已批准默沙东(MRK.US)的“first-in-class”疗法Winrevair(sotatercept)上市，用于治疗肺动脉高压(PAH)。信息显示，它具有成为治疗肺动脉高压的基石性疗法的潜力。这款疗法被行业媒体Evaluate评为2024年潜在重磅的疗法之一。据了解，Sotatercept是一款“first-in-class”的IIA型激活...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422431603?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-27 08:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422431603","market":"sh","top_or_hot":-1,"title":"默沙东(MRK.US)“first-in-class”疗法获FDA批准","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，3月27日，FDA官方网站显示已批准默沙东(MRK.US)的“first-in-class”疗法Winrevair(sotatercept)上市，用于治疗肺动脉高压(PAH)。信息显示，它具有成为治疗肺动脉高压的基石性疗法的潜力。这款疗法被行业媒体Evaluate评为2024年潜在重磅的疗法之一。据了解，Sotatercept是一款“first-in-class”的IIA型激活...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1093078.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东(MRK.US)“first-in-class”疗法获FDA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东(MRK.US)“first-in-class”疗法获FDA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-27 08:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1093078.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，3月27日，FDA官方网站显示已批准默沙东(MRK.US)的“first-in-class”疗法Winrevair(sotatercept)上市，用于治疗肺动脉高压(PAH)。信息显示，它具有成为治疗肺动脉高压的基石性疗法的潜力。这款疗法被行业媒体Evaluate评为2024年潜在重磅的疗法之一。据了解，Sotatercept是一款“first-in-class”的IIA型激活...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1093078.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1093078.html","article_id":"2422431603","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422431603","pubTimestamp":1711500294,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，3月27日，FDA官方网站显示已批准默沙东的“first-in-class”疗法Winrevair上市，用于治疗肺动脉高压。信息显示，它具有成为治疗肺动脉高压的基石性疗法的潜力。据了解，Sotatercept是一款“first-in-class”的IIA型激活素受体融合蛋白。Sotatercept是默沙东于2021年以约115亿美元收购Acceleron Pharma公司获得的关键疗法。此前，sotatercept已获得FDA授予的突破性疗法认定，这也是首款获得突破性疗法认定的肺动脉高压疗法。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","MRK":"默沙东","BK4559":"巴菲特持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4550":"红杉资本持仓","SG9999014542.SGD":"United Income Focus Trust Acc SGD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0238689110.USD":"贝莱德环球动力股票基金","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4516":"特朗普概念"},"translate_title":"Mercadon (MRK.US) \"first-in-class\" therapy approved by FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"智通财经APP获悉，3月27日，FDA官方网站显示已批准默沙东(MRK.US)的“first-in-class”疗法Winrevair(sotatercept)上市，用于治疗肺动脉高压(PAH)。信息显示，它具有成为治疗肺动脉高压的基石性疗法的潜力。这款疗法被行业媒体Evaluate评为2024年潜在重磅的疗法之一。据了解，Sotatercept是一款“first-in-class”的IIA型激活素受体(ActRIIA)融合蛋白。它将ActRIIA经过改造的细胞外域与抗体的Fc端融合在一起。它可以阻断激活素与细胞膜上的受体结合，从而降低激活素介导的信号传导。在临床前实验中它可以逆转肺动脉壁和右心室的重塑。Sotatercept是默沙东于2021年以约115亿美元收购Acceleron Pharma公司获得的关键疗法。此前，sotatercept已获得FDA授予的突破性疗法认定，这也是首款获得突破性疗法认定的肺动脉高压疗法。目前，全球有多款用于治疗PAH的靶向疗法正处于活跃研发后期阶段，均为小分子药物，且靶点多样。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422431603"}